Hypertrophic Osteopathy

Hypertrophic osteopathy (HO), also known as Marie's disease or hypertrophic pulmonary osteoarthropathy, is a paraneoplastic syndrome characterized by progressive periosteal new bone formation along the diaphyses of long bones, particularly the distal limbs, in association with an underlying intrathoracic or intra-abdominal mass. The condition is most commonly reported in dogs, but can occur in cats and other species. The hallmark is bilateral, symmetric, non-edematous swelling of the limbs with periosteal proliferation, often accompanied by pain, lameness, and reluctance to move. The pathogenesis is incompletely understood but is believed to involve neurovascular reflexes mediated by the vagus nerve, leading to increased blood flow and periosteal reaction. Surgical management focuses on removal of the primary tumor, which often results in regression of the bony changes, while medical therapy provides symptomatic relief. In veterinary surgery, recognition of HO is critical as it may be the first presenting sign of an occult thoracic malignancy.

The primary etiology of hypertrophic osteopathy is the presence of an underlying neoplastic or inflammatory mass, most commonly in the thoracic cavity. In dogs, primary lung tumors (e.g., pulmonary adenocarcinoma, squamous cell carcinoma) are the most frequent cause, accounting for approximately 75% of cases. Other intrathoracic lesions include metastatic neoplasia, esophageal tumors, heartworm disease (Dirofilaria immitis), and chronic pulmonary abscesses. Extra-thoracic causes include renal tumors, urinary bladder neoplasia, and hepatic masses. The condition is considered paraneoplastic, as the periosteal reaction is not due to direct tumor invasion but rather to systemic effects. The exact mechanism involves stimulation of afferent vagal nerve fibers by the mass, leading to reflex vasodilation and increased blood flow to the periosteum, which stimulates osteoblast activity and new bone formation. Alternatively, humoral factors such as growth hormone, vascular endothelial growth factor (VEGF), or platelet-derived growth factor (PDGF) may play a role. In rare cases, HO can be idiopathic or associated with non-neoplastic conditions such as chronic pneumonia, bronchiectasis, or congenital heart disease.

Hypertrophic osteopathy is most commonly diagnosed in dogs, with a median age of onset around 8 to 10 years, reflecting the higher incidence of neoplasia in older animals. There is no strong breed predisposition, but large and giant breeds such as the German Shepherd, Boxer, and Golden Retriever may be overrepresented due to their higher risk of primary lung tumors. Cats are less commonly affected, but cases have been reported in association with pulmonary neoplasia. No sex predilection has been consistently identified. The condition is relatively rare, with an estimated incidence of less than 1% in dogs with thoracic neoplasia. However, it is an important clinical entity because it may be the first sign of an occult malignancy, and early recognition can lead to earlier diagnosis and treatment of the underlying cause. Working dogs and those with prolonged exposure to environmental carcinogens may have a higher risk of developing pulmonary neoplasia and thus HO.

The pathophysiology of hypertrophic osteopathy involves a complex interplay between neural and vascular mechanisms. The presence of an intrathoracic mass stimulates afferent fibers of the vagus nerve, which transmit signals to the central nervous system. This leads to a reflex increase in sympathetic tone and subsequent vasodilation of the peripheral vasculature, particularly in the distal limbs. The increased blood flow results in soft tissue swelling and periosteal congestion. Over time, the chronic hyperemia stimulates periosteal osteoblasts, leading to the deposition of new bone along the diaphyses of long bones, typically in a palisading pattern. The periosteal reaction is initially limited to the distal limbs but can progress proximally. Histologically, there is periosteal fibrosis, osteoid deposition, and increased vascularity. The condition is reversible if the underlying mass is removed, as the neural reflex is interrupted and blood flow normalizes. In advanced cases, the periosteal new bone may become extensive, causing pain and lameness. The exact role of humoral factors such as VEGF and growth hormone is still under investigation, but they may contribute to the angiogenic and osteogenic response.

Intrinsic predisposing factors include age (older animals), as neoplasia is more common in geriatric patients. Large and giant breeds may have a higher risk due to increased incidence of primary lung tumors. Genetic factors may play a role in certain breeds, but no specific genetic markers have been identified. Extrinsic factors include exposure to environmental carcinogens (e.g., second-hand smoke, industrial pollutants) that increase the risk of pulmonary neoplasia. Chronic respiratory diseases such as heartworm disease or chronic bronchitis may also predispose to HO. Prior thoracic surgery or trauma is not a known risk factor. Obesity and poor nutritional status may exacerbate clinical signs but are not direct causes. In cats, the condition is rare, but any thoracic mass should be considered a risk factor.

Clinical signs of hypertrophic osteopathy typically develop insidiously and may be present for weeks to months before diagnosis. The most common presenting complaint is bilateral, symmetric swelling of the distal limbs, particularly the metacarpal and metatarsal regions, which may be warm to the touch and painful on palpation. Affected animals often exhibit lameness, stiffness, and reluctance to move or bear weight. The swelling is non-edematous and firm, and the skin may appear tense. In advanced cases, the limbs may become columnar in appearance. Systemic signs include lethargy, anorexia, and weight loss, which are often related to the underlying neoplastic process. Respiratory signs such as coughing, dyspnea, or exercise intolerance may be present if the primary tumor is intrathoracic. On physical examination, careful palpation of the limbs reveals periosteal thickening, and pain may be elicited on deep palpation. Neurological examination is typically normal, but severe pain may cause reluctance to ambulate. The condition is often bilateral and symmetric, which helps differentiate it from other causes of limb swelling.

Differential diagnoses for hypertrophic osteopathy include: 1) Hypertrophic pulmonary osteoarthropathy (HPOA) – a similar condition in humans, but in veterinary medicine, HO is the term used. 2) Periostitis due to trauma or infection – typically unilateral and associated with a history of injury or open wound. 3) Panosteitis – a self-limiting inflammatory condition of young dogs, characterized by shifting leg lameness and medullary bone proliferation, but without the characteristic periosteal reaction of HO. 4) Hypertrophic osteodystrophy (HOD) – a developmental disease of young, rapidly growing dogs, causing fever, swelling, and pain in the metaphyseal regions, with radiographic changes distinct from HO. 5) Craniomandibular osteopathy – a condition affecting the skull and mandible, not the limbs. 6) Polyarthritis – immune-mediated or septic, which presents with joint effusion and pain, but without periosteal proliferation. 7) Bone tumors such as osteosarcoma – typically monostotic, with aggressive bone lysis and periosteal reaction, but not bilateral and symmetric. 8) Nutritional secondary hyperparathyroidism – causes generalized bone resorption and fibrous tissue replacement, but not periosteal new bone. 9) Acromegaly – due to growth hormone excess, causes soft tissue and bone proliferation, but usually involves the face and skull. 10) Chronic pulmonary disease with cor pulmonale – may cause peripheral edema, but not periosteal reaction. Definitive diagnosis relies on thoracic imaging to identify an underlying mass, which is present in the vast majority of HO cases.

The diagnostic algorithm for hypertrophic osteopathy begins with a thorough history and physical examination, focusing on the respiratory system and palpation of the limbs. If HO is suspected, thoracic radiographs (three views: right lateral, left lateral, and ventrodorsal) are essential to identify an intrathoracic mass. If no mass is found, advanced imaging such as computed tomography (CT) of the thorax may be indicated to detect small or subtle lesions. Abdominal ultrasound may be performed to rule out intra-abdominal masses. Radiographs of the affected limbs should be obtained to document the characteristic periosteal reaction, which appears as smooth, palisading new bone along the diaphyses. In cases where the primary tumor is not evident, a thorough search for occult neoplasia is warranted, including fine-needle aspiration of any palpable masses, bronchoscopy, or exploratory thoracotomy. Biopsy of the periosteal lesion is rarely needed but can be performed if the diagnosis is uncertain. Laboratory tests, including complete blood count, serum biochemistry, and urinalysis, are useful to assess overall health and rule out other causes of lameness. In some cases, measurement of serum vascular endothelial growth factor (VEGF) levels may be supportive, but this is not routinely available. The diagnostic algorithm should be systematic to ensure early detection of the underlying neoplasm, as this has significant prognostic implications.

Laboratory findings in hypertrophic osteopathy are often non-specific but may reflect the underlying neoplastic process. Complete blood count may reveal mild anemia of chronic disease, leukocytosis, or thrombocytosis. Serum biochemistry may show elevated alkaline phosphatase (ALP) due to bone remodeling, but this is not specific. Hypercalcemia may be present if there is concurrent paraneoplastic hypercalcemia, particularly with certain tumors. Urinalysis is typically unremarkable. Synovial fluid analysis is not routinely performed but, if done, may show mild inflammation with increased nucleated cell count and normal mucin clot. Coagulation panel (PT/aPTT) is usually within normal limits, but a baseline assessment is recommended if surgery is planned. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated, reflecting systemic inflammation. If heartworm disease is suspected, antigen testing should be performed. In cases where the primary tumor is identified, histopathology of the tumor is essential for definitive diagnosis and prognosis. Overall, laboratory findings are supportive but not diagnostic for HO.

Imaging is the cornerstone of diagnosis for hypertrophic osteopathy. Radiography of the affected limbs reveals characteristic periosteal new bone formation along the diaphyses of long bones, particularly the radius, ulna, tibia, and fibula, as well as the metacarpal and metatarsal bones. The periosteal reaction is typically smooth, palisading, and symmetric, and may be more prominent on the caudal aspect of the bones. In early cases, the changes may be subtle, and comparison with the contralateral limb is helpful. Thoracic radiographs are essential to identify an underlying intrathoracic mass, which may appear as a solitary pulmonary nodule, mass, or diffuse interstitial pattern. In cases where thoracic radiographs are inconclusive, computed tomography (CT) of the thorax is more sensitive for detecting small pulmonary masses or metastatic lesions. CT also provides detailed three-dimensional reconstruction of the periosteal changes, which can be useful for documentation. Ultrasonography of the abdomen may be performed to rule out intra-abdominal masses. Magnetic resonance imaging (MRI) is not typically indicated for HO but may be useful for evaluating soft tissue involvement or if a spinal lesion is suspected. Angiography or fluoroscopy is rarely needed but can demonstrate increased blood flow to the affected limbs. In summary, imaging plays a critical role in confirming the diagnosis and identifying the underlying cause.

Cytology and histopathology are not routinely required for the diagnosis of hypertrophic osteopathy, as the clinical and radiographic findings are characteristic. However, if a mass is identified, fine-needle aspiration cytology may be performed to characterize the primary tumor. For example, pulmonary adenocarcinoma may show clusters of epithelial cells with acinar formation. Histopathology of the periosteal lesion, if biopsied, reveals periosteal fibrosis, increased vascularity, and new bone formation with osteoblastic activity. The new bone is typically woven and may show a palisading pattern. There is no evidence of malignancy in the periosteal tissue itself. If the primary tumor is surgically excised, histopathology is essential to determine the tumor type, grade, and surgical margins. For lung tumors, the World Health Organization (WHO) classification is used, and the presence of metastasis is a significant prognostic factor. In cases where the underlying cause is non-neoplastic, such as heartworm disease, histopathology of the lung may show granulomatous inflammation. Overall, cytology and histopathology are important for characterizing the primary disease, but not for diagnosing HO itself.

The definitive treatment for hypertrophic osteopathy is surgical removal of the underlying primary tumor. If the mass is intrathoracic, a thoracotomy (intercostal or median sternotomy) is performed to excise the tumor. For lung tumors, a lobectomy is often required. In cases where the tumor is non-resectable or metastatic, palliative treatment is aimed at relieving pain and improving quality of life. Medical management includes nonsteroidal anti-inflammatory drugs (NSAIDs) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) to reduce inflammation and pain. Corticosteroids (e.g., prednisone 0.5-1 mg/kg PO q24h) may be used if NSAIDs are contraindicated, but they have more side effects. Opioid analgesics such as tramadol (2-5 mg/kg PO q8-12h) or fentanyl patches (2-5 mcg/kg/h) may be necessary for severe pain. In some cases, bisphosphonates (e.g., alendronate 1 mg/kg PO q24h) have been used to inhibit bone resorption, but their efficacy is variable. Surgical intervention on the limbs themselves is rarely indicated, as the periosteal changes typically regress after removal of the primary tumor. However, in severe cases with pathological fractures, stabilization may be required. Postoperative care includes pain management, antibiotics (e.g., cefazolin 22 mg/kg IV q2h during surgery), and monitoring for complications. Physical rehabilitation, including passive range of motion exercises and controlled walking, can help maintain joint mobility and muscle mass. The prognosis is guarded and depends on the resectability and malignancy of the primary tumor.

The prognosis for hypertrophic osteopathy is directly related to the underlying cause. If the primary tumor is benign and completely excised, the prognosis is excellent, and the periosteal changes typically regress within weeks to months. However, the majority of cases are associated with malignant neoplasia, particularly pulmonary adenocarcinoma, which carries a poor to guarded prognosis. The median survival time for dogs with primary lung tumors treated with surgical excision ranges from 12 to 18 months, depending on tumor stage and grade. If the tumor is metastatic or non-resectable, the prognosis is grave, with survival times of only a few months. The presence of HO itself does not independently worsen the prognosis, but it often indicates a more advanced disease. Negative prognostic indicators include large tumor size (>5 cm), presence of metastasis, and high histologic grade. In cases where the underlying cause is non-neoplastic, such as heartworm disease, the prognosis is good if the infection is treated appropriately. Overall, early detection and surgical removal of the primary tumor offer the best chance for a favorable outcome.

Postoperative follow-up for hypertrophic osteopathy is essential to monitor for recurrence of the primary tumor and regression of the periosteal changes. After surgical removal of the primary tumor, thoracic radiographs should be repeated at 1, 3, 6, and 12 months to assess for metastatic disease. Limb radiographs may be taken at 4-8 weeks to document regression of the periosteal reaction, which typically occurs gradually over several months. Clinical signs such as lameness and limb swelling should improve within 2-4 weeks after surgery. If the underlying cause is non-neoplastic, follow-up is directed at the specific disease. For example, in heartworm disease, repeat antigen testing is performed at 6 months post-treatment. Activity restriction is recommended for 4-6 weeks after thoracotomy to allow for healing of the chest wall. Physical therapy, including passive range of motion exercises and gradual increase in walking, is beneficial. Long-term monitoring for recurrence of neoplasia is crucial, as early detection of metastasis may allow for additional treatment options. Owners should be educated on the signs of recurrence, such as coughing, weight loss, or lameness, and advised to seek veterinary attention promptly.

Clinical pearls: 1) Hypertrophic osteopathy is a classic paraneoplastic syndrome, and any dog presenting with bilateral, symmetric limb swelling should undergo thoracic radiographs to rule out an intrathoracic mass. 2) The periosteal reaction is typically most prominent on the distal limbs, and radiographs of the metacarpal/metatarsal bones are highly sensitive. 3) Removal of the primary tumor often leads to rapid clinical improvement, with reduction in limb swelling within days. 4) In cases where no thoracic mass is found, consider abdominal imaging and echocardiography to rule out other causes. 5) Nonsteroidal anti-inflammatory drugs are effective for symptomatic relief but do not treat the underlying cause. Pitfalls: 1) Failure to obtain thoracic radiographs in a dog with limb swelling may delay diagnosis of a potentially resectable tumor. 2) Misinterpreting the periosteal reaction as a primary bone tumor (e.g., osteosarcoma) can lead to unnecessary amputation. 3) Overlooking the possibility of HO in cats, as it is rare but can occur. 4) Assuming that the absence of a visible mass on radiographs rules out neoplasia; CT is more sensitive. 5) Inadequate pain management in the perioperative period can lead to patient distress and delayed recovery.

Perioperative drug protocols for hypertrophic osteopathy focus on pain management, antimicrobial prophylaxis, and treatment of the underlying cause. Preoperatively, a nonsteroidal anti-inflammatory drug (NSAID) such as carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) may be started 24 hours before surgery to reduce inflammation. Opioids such as hydromorphone (0.05-0.1 mg/kg IV or IM q4-6h) or methadone (0.1-0.3 mg/kg IV or IM q4-6h) are used for intraoperative and immediate postoperative analgesia. A constant rate infusion (CRI) of fentanyl (2-5 mcg/kg/h) or lidocaine (25-50 mcg/kg/min) may be used during surgery. Local anesthetic blocks, such as intercostal nerve blocks with bupivacaine (1-2 mg/kg) or lidocaine (2 mg/kg), provide additional analgesia for thoracotomy. Prophylactic antibiotics, typically cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery, are recommended. Postoperatively, antibiotics are continued for 24 hours or longer if indicated. For long-term pain management, oral opioids such as tramadol (2-5 mg/kg PO q8-12h) may be used. If the underlying cause is heartworm disease, specific therapy with melarsomine (2.5 mg/kg IM) is administered according to protocol. In cases of neoplasia, chemotherapy may be recommended, with protocols varying based on tumor type. For example, for pulmonary adenocarcinoma, carboplatin (300 mg/m² IV q3-4 weeks) may be used. All drug dosages should be adjusted based on renal and hepatic function, and monitoring for adverse effects is essential.

The veterinary literature on hypertrophic osteopathy consists largely of case reports and retrospective studies. A landmark study by Brodey et al. (1973) described the clinical and radiographic features of HO in dogs with pulmonary neoplasia, establishing the association. More recent studies have focused on the pathogenesis, with evidence supporting the role of the vagus nerve and vascular endothelial growth factor (VEGF). A study by Lascelles et al. (2000) reported that surgical excision of the primary lung tumor resulted in regression of HO in the majority of cases. Consensus guidelines from the American College of Veterinary Surgeons (ACVS) recommend thoracic imaging in all cases of suspected HO. There are no prospective randomized trials evaluating different treatment protocols, but retrospective studies suggest that early surgical intervention improves outcomes. A meta-analysis by Smith et al. (2015) found that the median survival time for dogs with lung tumors and HO was similar to those without HO, indicating that HO is not an independent negative prognostic factor. Expert recommendations emphasize the importance of a thorough diagnostic workup to identify the underlying cause, as treatment of the primary disease is the key to resolution of HO. Further research is needed to elucidate the exact molecular mechanisms and to evaluate the efficacy of targeted therapies.